⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RNAZ News
TransCode Therapeutics, Inc. Common Stock
CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development
accessnewswire.com
RNAZ
DWTX
Form 8-K
sec.gov
RNAZ
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer
prnewswire.com
RNAZ
Form 8-K
sec.gov
RNAZ
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
prnewswire.com
RNAZ
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
prnewswire.com
RNAZ
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
prnewswire.com
RNAZ
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
prnewswire.com
RNAZ
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
prnewswire.com
RNAZ
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
prnewswire.com
RNAZ